CNBX Pharmaceuticals uses 8 technology products and services including WordPress, MySQL, Google Fonts API, and more. Explore CNBX Pharmaceuticals's tech stack below.
WordPress
Content Management System
MySQL
Database
Google Fonts API
Font Scripts
JSON-LD
Javascript Frameworks
X-XSS-Protection
Security
X-Content-Type-Options
Web & Portal Technology
HTTP/3
Web & Portal Technology
MailChimp for WordPress
Web Platform Extensions
Media & News
CNBX Pharmaceuticals's Email Address Formats
CNBX Pharmaceuticals uses at least 2 format(s):
CNBX Pharmaceuticals Email Formats
Example
Percentage
First@cannabics.com
John@cannabics.com
87%
FirstLast@cannabics.com
JohnDoe@cannabics.com
13%
Frequently Asked Questions
Where is CNBX Pharmaceuticals's headquarters located?
CNBX Pharmaceuticals's main headquarters is located at Bethesda, Maryland 20814 United States. The company has employees across 3 continents, including North AmericaAsiaEurope.
What is CNBX Pharmaceuticals's phone number?
You can contact CNBX Pharmaceuticals's main corporate office by phone at
+1-877-424-****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.
What is CNBX Pharmaceuticals's official website and social media links?
CNBX Pharmaceuticals's official website is cnbxpharma.com and has social profiles on LinkedIn.
What is CNBX Pharmaceuticals's NAICS code?
CNBX Pharmaceuticals's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.
How many employees does CNBX Pharmaceuticals have currently?
As of April 2026, CNBX Pharmaceuticals has approximately 6 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Chief Executive Officer: E. B.Chief Financial Officer: U. B.Co Founder And Ceo: E. B.. Explore CNBX Pharmaceuticals's employee directory with LeadIQ.
What industry does CNBX Pharmaceuticals belong to?
CNBX Pharmaceuticals is a publicly traded company (CNBX: OTCQB) and developer of the world’s first cannabinoid-based antitumor drug candidate for the treatment of colorectal cancer based on the company's novel and proprietary formulation CNBX™️ RCC-33.